Hepatitis C virus (HCV) is a global public health problem involving chronic infection of the liver, which can cause liver disease and is linked with liver cancer. Viral innate immune evasion strategies and human genetic determinants underlie the transition of acute HCV infection to viral persistence and the support of chronic infection. Host genetic factors, such as sequence polymorphisms in IFNL3, a gene in the host interferon system, can influence both the outcome of the infection and the response to antiviral therapy. Recent insights into how HCV regulates innate immune signaling within the liver reveal a complex interaction of patient genetic background with viral and host factors of innate immune triggering and control that imparts the outcome of HCV infection and immunity.
Hepatitis C virus (HCV) is a global public health problem involving chronic infection of the liver, which can cause liver disease and is linked with liver cancer. Viral innate immune evasion strategies and human genetic determinants underlie the transition of acute HCV infection to viral persistence and the support of chronic infection. Host genetic factors, such as sequence polymorphisms in IFNL3, a gene in the host interferon system, can influence both the outcome of the infection and the response to antiviral therapy. Recent insights into how HCV regulates innate immune signaling within the liver reveal a complex interaction of patient genetic background with viral and host factors of innate immune triggering and control that imparts the outcome of HCV infection and immunity.
HCV is highly successful at establishing a chronic infection HCV is a major public health problem that infects approximately 170 million people worldwide 1 . Infection occurs within hepatocytes, the chief parenchymal cell of the liver. HCV typically causes a chronic infection and is a major cause of liver disease and liver cancer, and it often necessitates liver transplantation 2 . The first line of immune defense against HCV relies on cell-intrinsic innate immunity within hepatocytes. This innate immune response serves to recognize HCV as nonself and induces local antiviral defenses in the infected cell and liver tissue that can function to recruit and modulate the actions of immune cells of the adaptive immune response. Hepatic innate immunity is therefore essential for controlling the outcome of HCV infection and immunity. However, the majority of those infected with HCV fail to mount a productive immune response that clears infection. Underscoring this problem is that HCV has evolved multiple mechanisms to regulate and evade innate immunity, thus providing a foundation for chronic infection. The standard-of-care therapy for HCV infection has been treatment with pegylated interferon-a (IFN-a) plus ribavirin. As an antiviral cytokine, IFN is an innate immune therapeutic but is very unpleasant for the patient, and for those infected with the difficult-to-treat HCV genotypes (1 and 4) it is only curative 40-50% of the time 3 . Although first-generation direct-acting antiviral drugs are now being introduced into the clinic, they are applied in combination with IFN to enhance efficacy and reduce chances for viral resistance breakthrough 4, 5 . Moreover, another underlying factor in HCV infection outcome is polymorphism in IFNL3 (also referred to as IL28B), a human gene of the host system of innate antiviral defense, and these polymorphisms can influence both the outcome of infection and response to therapy [6] [7] [8] [9] [10] . Understanding how HCV regulates hepatic innate immune responses is essential for guiding the improvement of HCV therapy, developing effective vaccine applications and designing new therapeutic strategies to control infection and suppress liver disease. In this Perspective, we will describe how virus and host control of innate immune factors contributes to HCV persistence in the liver and how these virus-host interactions affect the outcome of infection, immunity and current IFN-based antiviral therapy.
The host response to HCV infection HCV is a hepacivirus and member of the Flaviviridae family. The viral genome is a single copy of positive-sense RNA. After entry into hepatocytes, the virus uncoats and the viral genome is translated into a single polyprotein that is co-and post-translationally processed into structural and nonstructural proteins by a combination of host peptidases and two viral-encoded proteases. The HCV nonstructural proteins assemble as a replication complex onto modified intracellular membranes to replicate the HCV genome. This process involves the production of an antigenomic replication-intermediate RNA and probably an accumulation of double-stranded RNA (dsRNA) intermediate products. The new viral genomes are packaged into viral particles by the viral structural proteins. The resulting virus is released from the hepatocyte in association with host lipoproteins, such that in the blood HCV is present as a lipoprotein-coated virus 11 . During the viral replication process HCV is sensed as nonself by pattern recognition receptors (PRRs) in the host cell that identify and bind pathogen-associated molecular patterns (PAMPs) within viral products, leading to coordinated activation of the innate immune response and adaptive immune responses. Both the innate and adaptive arms of immunity, including cross-talk between liver-resident and infiltrating cells (such as hepatocytes, Kupffer cells, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells and other immune cells), contribute to the host's ability to resolve HCV infection [12] [13] [14] . However, despite these immune defenses, HCV infection becomes chronic in about 70-80% of those who are acutely infected 2 . This outcome is due to a combination of host and viral factors that regulate the intracellular innate immune response against HCV. Importantly, inactivation of this intracellular innate immune response by HCV may also result in a nonfunctional adaptive immune response. Indeed, PRR signaling (specifically by mitochondrial antiviral signaling protein (MAVS)) is required for functional innate and adaptive responses during infection with West Nile virus, a related virus of the Flaviviridae family 15 . Although outside of the scope of this Perspective, a functional adaptive immune response is also essential for resolving HCV infection (reviewed in refs. 14,16). nucleic acid-binding proteins can also serve as putative PRRs when their engagement of viral nucleic acid results in their interaction with and regulation of specific PRR signaling pathways. Protein kinase R (PKR) is an example of a nontraditional PRR, and its dsRNA-binding activity promotes its interaction with MAVS to impart PRR signaling of innate immunity 17, 18 .
We have shown that HCV is recognized by RIG-I within hours of infection and activates downstream signaling before extensive viral protein synthesis 19 . RIG-I signaling during HCV infection is initiated upon its binding of PAMP RNA that includes an exposed 5ʹ triphosphate and the 3ʹ untranslated region of the HCV genome RNA, which is rich in poly-U/UC ribonucleotides 20, 21 . This multicomponent Detection of HCV A variety of PRRs sense viruses as foreign invaders within the host cell through specific PAMP recognition to activate innate immune signaling. The retinoic acid inducible gene-I (RIG-I)-like receptors, RIG-I and melanoma differentiation antigen 5 are cytosolic PRRs that sense RNA viruses. Toll-like receptors (TLRs) mediate virus sensing from within endosomal compartments to signal innate defenses, whereas Nod-like receptors serve to sense cytosolic viral products or viral metabolites to drive inflammatory responses. Activation of these PRRs drives the innate antiviral and proinflammatory responses that limit virus replication and spread while also serving to recruit adaptive immune cells and enhance their effector actions at the site of infection. A variety of other Marina Corral Spence P E R S P E C T I V E npg site (IRES) translation mechanism that is insensitive to the levels of eIF2a phosphorylation that suppress cap-dependent translation of host mRNAs [36] [37] [38] [39] . It is now known that PKR binding of HCV dsRNA also activates a kinase-independent signal transduction cascade that drives induction of specific IFN-stimulated genes (ISGs) and IFN-b production by signaling through MAVS, TNF receptor-associated factor 3, IRFs and NF-kB, all before RIG-I activation 17, 18, 35 (Fig. 1) 44 . The NS3-NS4A protease complex is anchored to intracellular membranes through the NS4A transmembrane domain and an amphipathic a-helix at the NS3 N terminus that facilitates membrane association and cleavage of membrane-anchored substrates 45, 46 . NS3-NS4A can block RIG-I signaling, because in addition to proteolytically processing the HCV polyprotein, NS3-NS4A targets and cleaves MAVS from intracellular membranes to prevent signal transduction 19, [47] [48] [49] [50] [51] (Fig. 2) . As MAVS must be anchored to membranes for downstream signaling, this cleavage event prevents activation of the RIG-I pathway during acute infection, abrogates IFN induction and supports the progression to chronic infection. However, we note that other hepatotropic viruses, including hepatitis A virus (HAV) and GB virus B (GVB-B), encode proteases that also cleave MAVS 52, 53 . Although GVB-B can mediate a chronic infection in marmosets 54 , HAV does not generally become chronic. Thus, MAVS cleavage is probably necessary but not sufficient for viral chronicity. NS3-NS4A cleavage of MAVS was previously thought to occur at the mitochondrial outer membrane, a primary site of MAVS localization 19, 51, 55, 56 . However, it is now known that the MAVS transmembrane PAMP motif presents a nonself RNA signature that is detected by RIG-I to activate innate immunity. Although the 5ʹ triphosphate and the poly-U/UC region are at opposite ends of the viral genome, known intragenome interactions between the 5ʹ and 3ʹ ends of the RNA 22 can bring both into proximity for RIG-I binding and activation by HCV replication intermediates. HCV PAMP could be presented to RIG-I either from incoming genomes after viral uncoating or during HCV genome amplification. HCV RNA binding induces a RIG-I conformational change that promotes its oligomerization and translocation from the cytosol into intracellular membranes [23] [24] [25] . This process requires interactions with the chaperone protein 14-3-3e and the E3 ubiquitin ligase TRIM25, which together with RIG-I make up a translocon that facilitates the interaction of RIG-I with MAVS 24, 26 . The RIG-I-MAVS interaction promotes the formation of a MAVS signalosome that propagates activation of downstream effector molecules, including the transcription factors interferon regulatory factor-3 (IRF-3) and nuclear factor-kB (NF-kB) and a variety of proinflammatory cytokines 27 (Fig. 1) .
TLR3 has also been implicated as a PRR that senses HCV, although its role in HCV detection and immunity is still not fully understood. TLR3 is an endosomal sensor of dsRNA expressed in a number of cell types within the liver, including hepatocytes and the liver-resident macrophage Kupffer cells 28, 29 . TLR3 signals are transmitted through the adaptor protein TIR-domain-containing adaptor-inducing interferon-β (TRIF), which activates IRF-3 and NF-kB for the production of type I IFN, proinflammatory cytokine and chemokines, as well as for apoptotic signaling 30, 31 (Fig. 1) . Whereas synthetic dsRNA ligands of TLR3 can induce IRF-3-dependent signaling in cells expressing ectopic TLR3 within 24 h 28 , HCV infection in these cells activates this signaling, including cytokine production, at later times (3-4 d) after infection 28, 32 . The TLR3 ligand of HCV has recently been identified as HCV dsRNA replication intermediates that accumulate late during HCV replication and interact with the dsRNA-binding domain of TLR3 32 . It is unlikely that incoming viral genomes or early replication products serve as TLR3 ligands, as TLR3-based cytokine production requires several days to be induced. Instead, the HCV ligands of TLR3 are probably present either after uptake of extracellular HCV dsRNA (either from dying cells or from the extracellular milieu) by scavenger receptors on nearby uninfected cells 33 or after accumulation of dsRNA viral-replication intermediates, which could be exposed to TLR3 in either the endosome or autophagic vesicles 34 . Therefore, during HCV infection, TLR3-mediated signaling could serve as a secondary innate immune detection or surveillance system for uninfected cells after initial RIG-I detection of HCV, and it could be involved in setting up an antiviral state within regions of the liver or for chemokine induction to recruit T cells to the liver during HCV infection 32 . Interestingly, the cytokine induction profile after TLR3 activation by HCV is distinct from that induced by the dsRNA mimic polyinosine-cytosine, suggesting that the HCV-TLR3 interaction has a level of specificity 28, 32 . It is possible that the induction of the antiviral and proinflammatory responses by TLR3 and RIG-I could contribute to HCV-mediated pathogenesis, including liver inflammation and fibrosis progression during chronic infection, although the mechanisms of such immunopathogenesis are unknown. Additionally, the roles of TLR3 and RIG-I signaling in mediating HCV liver disease in vivo are not known.
Recent studies have now reclassified the well-known HCV antiviral protein kinase PKR as a genuine PRR for HCV that activates and contributes to innate immune signaling and IFN production 35 . PKR is a dsRNA-binding protein whose kinase activity can be induced by binding to HCV dsRNA to phosphorylate the a subunit of eukaryotic initiation factor 2 (eIF2a). This suppresses host mRNA translation, but not HCV translation, because HCV uses an internal ribosome entry P E R S P E C T I V E npg and how they would support this viral persistence are still unclear (Fig.  2) . It is possible that NS5A and E2 inactivation of PKR-translational suppression could function only at specific times during infection (for example, after NS3-NS4A suppression of MAVS-dependent signaling) to ensure the requisite synthesis of host factors required to maintain cellular growth while supporting an environment for persistent HCV replication.
Innate immune regulation might determine IFN therapy response IFN-based therapies are the standard course of therapy for HCV. IFN is an antiviral cytokine that induces the expression of hundreds of ISGs, many of which have antiviral or immunomodulatory activities that can limit virus replication and spread and prime the adaptive immune response to HCV infection 65 . In fact, in acutely infected patients, IFN therapy is extremely successful at preventing chronic infection 66 . However, in chronically infected patients, the response to IFN-based therapies is variable, and many patients maintain high levels of HCV viremia in spite of IFN treatment. We propose that the low effectiveness domain also anchors the protein at diverse sites within an intracellular membrane network at peroxisomes and on mitochondrial-associated membranes (MAMs), an endoplasmic reticulum (ER) membrane subdomain residing at junctions between the ER and mitochondria 57, 58 . The NS3-NS4A protease complex localizes to all of these membranes during HCV infection 58 . However, rather than cleaving MAVS from the outer mitochondrial membrane, NS3-NS4A targets and cleaves the MAM-localized MAVS. This process abrogates RIG-I signaling despite some intact MAVS remaining on the mitochondria 58 . Therefore, during HCV infection, the MAMresident MAVS probably transduces RIG-I pathway signaling. Cleavage of MAVS during HCV infection has also been shown in vivo in the liver of patients with chronic HCV infection 19, 59 . Importantly, patients with cleaved MAVS showed lower levels of IFN pathway activation 59 . Thus, MAVS cleavage by the HCV NS3-NS4A protease disrupts RIG-I signaling of innate antiviral immunity and attenuates IFN production.
The HCV NS3-NS4A protease also proteolytically targets TRIF 60 , the TLR3 signalingadaptor protein. Cell culture studies have shown that TRIF is cleaved by NS3-NS4A in vitro 60 . Although specific TRIF proteolytic fragments have not been detected during HCV infection, the relative abundance of TRIF protein is decreased, probably as a result of destabilization and degradation following cleavage 28 . NS3-NS4A cleavage of TRIF suggests that control of TLR3 signaling must be important for successful HCV infection, perhaps by preventing excess inflammation that could impart viral suppression or by blocking chemokine induction required for vigorous cytotoxic T cell responses known to be important for HCV clearance 16 . TLR3-independent RNA-sensing mechanisms that signal through TRIF to impart innate immunity and inflammatory responses have also been described 61 , and NS3-NS4A targeting of TRIF may also contribute to HCV persistence by blocking their actions during infection.
HCV regulates PKR activity during viral infection; however, this regulation is complex and need to be redefined in the context of PKR having seemingly opposing pro-and anti-HCV roles during infection [35] [36] [37] . PKR-mediated translational suppression of host mRNAs during HCV infection and IFN therapy can inhibit translation of host factors important for HCV replication and cellular growth (PKR functions as an antiviral molecule) but it can also inhibit translation of ISGs and IFN (PKR functions as a proviral molecule) 36, 37 . Furthermore, PKR-kinase independent signaling during HCV infection to activate specific ISGs and IFN-b would be considered to be antiviral. It is known that HCV has several PKR-inactivation strategies that probably contribute to viral persistence and/or IFN therapy responses, both at the level of PKR/PRR signaling (direct actions of viral NS5 and E2 on PKR; NS3-NS4A cleavage of MAVS) and at the level of PKR-regulated translational inhibition (NS5A and E2 (refs. 62-64) ), but the exact mechanisms and timing (5); HCV E2 and NS5A proteins inactivate PKR-dependent activation of the host translation factor eIF2a to reactivate protein translation during infection (2).
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Although IFN therapy induces many anti-HCV ISGs (see Table 1 ) 69 , it is unlikely that any single ISG or its regulation by HCV completely governs the outcome of IFN therapy during HCV infection 73 . Furthermore, within the liver, there is no single ISG among all of those expressed before therapy that is associated with poor response to treatment; instead, it is the overall composition of induced ISGs that associates with poor therapy responses 69, 74, 75 . Indeed, it is probably a combination of factors mediating control of innate immune and IFN signaling, along with viral and host genetic variability (to be discussed below), that all contribute to the differential responses to IFN-based therapy in patients with HCV.
of IFN therapy in those chronically infected with HCV can be attributed to a combination of viral and host factors that contribute to regulation of IFN action and treatment-induced clearance (Fig. 3) . The viral factor that most highly predicts IFN treatment response is the viral genotype. There are six major HCV genotypes defined by their sequence conservation, and there is variation that further divides them as subtypes and viral quasispecies 67 . Interestingly, patients infected with different HCV genotypes have different therapy responses. Patients infected with HCV genotype 2 or 3 show the highest response rates to therapy, with 70-80% of these patients achieving a sustained virologic response (SVR), whereas only 45-60% of patients with HCV genotype 1 or 4 infection achieve SVR (summarized in ref. 68 ). Indeed, HCV genotypes 1 and 4 induce high levels of hepatic ISG expression in the infected patient liver before therapy, resulting in an IFN-insensitive phenotype that attenuates treatment responses [69] [70] [71] .
What explains the differences in therapy responses associated with viral genotype? Further, why does HCV persist in the liver in spite of high levels of IFN signaling and elevated expression of hepatic ISGs, many with known antiviral actions? Within the HCVinfected hepatocyte, HCV proteins, including core, could be antagonizing IFN signaling through Jak-signal transducer and activator of transcription (STAT) pathway inactivation (reviewed in ref. 42) or suppression of specific ISGs that could otherwise limit HCV infection (Fig. 3) . Additionally, there are known genotypic differences in HCV-mediated immune regulation that probably contribute to the observed differences in therapy responses. For example, NS5A and E2 from different genotypes differentially bind and regulate PKR, with the IFN-resistant viral genotypes being better able to block PKR function [62] [63] [64] . Importantly, the viral sequences encoding E2 (which has a PKR inhibitory domain) and NS5A (which has a PKR-binding domain) show the most evolution between HCV genotypes, supporting the idea that E2 and NS5A are potential determinants of genotype-specific clinical outcome 68 . In addition, differential levels of MAVS cleavage among HCV genotypes were found in the livers of patients with HCV: those with fully cleaved MAVS (genotypes 2 and 3) showed lower levels of pretherapy ISG expression 59 . Interestingly, higher pretherapy genetic variability of HCV within the major genotypes, especially within the sequences of core, NS3 and NS5A, correlates with a more successful therapy outcome 72 . Taken together, these data suggest that alterations in the sequences of these viral regulatory factors lead to increased immune regulation during HCV infection. This increased immune regulation, although beneficial to the virus, would be predicted to prevent pretherapy induction of ISGs and thereby make this virus more susceptible to HCV therapy. 89 , and it can function cooperatively with type I IFN to impart enhanced ISG induction and antiviral activity 90 . Therefore, in the innate immune response to HCV, IFN-l may provide a localized, sustained activation of ISGs in specific cell types in the infected liver and may prime an effective immune response, both at the innate and adaptive levels, for HCV clearance. In fact, IFN-l has emerged as new candidate for HCV therapy with fewer side effects than IFN-a 86 , probably owing to its restricted receptor distribution. It is still not clear why the genetic polymorphisms associated with natural and therapy-induced control of HCV are found specifically in IFNL3 (and now IFNL4), and not within the IFNL1 or IFNL2 loci, and why IFNL3 specifically would have such a key role in the host response to HCV. More studies aimed at understanding how these very similar genes are activated and regulated during HCV infection and at determining both the cell types of production and the mechanism of induction of the IFN-l cytokines during HCV infection are needed. In particular, new studies need to continue to carefully discriminate between the virtually indistinguishable IFNL2 and IFNL3 genes, at both the protein and mRNA levels. Moreover, there is a need to actually demonstrate the expression IFNL4 (both protein and mRNA) and its regulation in patients, as well to understand the effect of IFNL4 SNPs on IFNL3 expression 85 . Only then will there be a foundation for understanding the role of the IFN-l cytokines in HCV immune control and response to therapy in the liver.
Patient genetic differences affect HCV infection outcomes
Although viral genotype differences influence clinical outcome to IFNbased therapies, host genetic differences also play a part in this outcome. Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) upstream of the IFNL3 locus that can predict both successful clinical outcome to HCV therapy 6,7,9,10 and spontaneous HCV clearance 8, 10 . These SNPs associate with altered mRNA expression of IFNL3, which encodes the antiviral cytokine IFNL3, which suggests that IFNL3 expression levels are probably associated with HCV clearance and response to therapy 6, 7, 70 . Although several early studies failed to find altered mRNA expression of IFNL3 associated with these SNPs 74, 76 , since the specificity of real-time PCR primers for IFNL3 has increased (to differentiate between IFNL3 and the closely related IFNL2), it is now clear that SNPs in the IFNL3 locus do affect the expression of IFNL3 within the liver, peripheral blood mononuclear cells and whole blood 6, 7, 70, 77, 78 , with the minor (unfavorable) allele resulting in less IFNL3 expression. Detailed analyses of the SNPs within the haplotype block at the IFNL3 gene locus have revealed candidate functional SNPs involved in both natural and treatment-based clearance of HCV (Fig. 4) [79] [80] [81] . However, studies of the function of these genetic elements have not yet defined the single causal variants and how these variations regulate IFNL3 mRNA expression. The locations of the current candidate casual SNPs within the IFNL3 gene suggest possible regulatory mechanisms (see Fig. 4 ). As the SNPs in IFNL3 do seem to affect IFNL3 expression 6, 7, 70, 77, 78, 82 , it is unlikely that these SNPs are simply in linkage disequilibrium with some other gene involved in HCV pathogenesis. Defining how IFNL3 polymorphisms enhance HCV therapy response rates will be important for the development of new therapeutic strategies to suppress HCV through treatment with recombinant IFN-l and to better understand the role of IFNL3 in the host response to HCV infection. A recent study showed that patients with the unfavorable IFNL3 genotype have depressed innate immune function, particularly with respect to NK cells 83 , suggesting the decreased expression of IFNL3 affects immunity and therefore clearance of HCV.
Additionally, a dinucleotide polymorphism that can create or disrupt an open reading frame for a newly characterized gene, IFNL4, has been identified 84, 85 (Fig. 4) . In this case, it has been proposed that loss of expression of IFNL4 is protective for HCV. Given the current data, it is still not clear what the role is, if any, for IFNL4 in the differential responses to HCV therapy, but it is clear that the IFN-l locus is important for immune control of HCV infection.
The type III IFNs (IFN-l) now include IFNL3 and the closely related cytokines IFNL1, IFNL2 and IFNL4. As IFNL4 shares only 29% amino acid identity with the other IFN-l family members and functions in a slightly different manner 84 , we will limit our discussion here to IFNL1, IFNL2 and IFNL3. These cytokines have antiviral and immunomodulatory activity similar to that of the type I IFNs. IFN-l signals through a receptor consisting of the IL10R2 and IFNLR1 subunits that converges on the Jak-STAT pathway, induces similar ISG profiles as type I IFN and can inhibit HCV replication in vitro (reviewed in ref. 86 ). However, the cellular producers and receptor proteins for type III IFN have a more limited distribution than type I IFN 87 , suggesting a more 
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npg is being produced endogenously during infection. The cell type of type I or type III IFN production could be the infected cell as well as bystander cells responding to virus exposure 33, 75, 94 . Importantly, the fact that patients with the favorable IFNL3 SNPs generally have higher levels of IFNL3 and lower pretherapy hepatic ISG levels, but higher macrophage ISG levels 91 , suggests that other cell types within the liver aside from the infected hepatocytes could be producing the IFN. Further, production of type I and/or type III IFN or response to the IFN at the level of the receptor or downstream signaling in the infected hepatocyte is probably regulated by HCV infection itself. It is known that this is the case for type 1 IFN, and it is quite possible that this is also true for IFNL3 (Figs. 2 and 3) .
Here, we propose a number of virus-host interactions in the context of the liver that could drive the hepatic production of IFN and proinflammatory cytokines (Fig. 5) . Before viral proteins accumulate during infection, HCV activation of RIG-I and/or PKR actions in hepatocytes can stimulate IRF-3 activation, leading to an early, albeit transient, induction of IFN-b and ISG expression 35, 36, 95 . HCV can also induce type III IFN in primary liver cultures 96, 97 . Resident or infiltrating liver myeloid cells, including pDCs and Kupffer cells, could produce type I or type III IFN after stimulation by viral products from neighboring infected hepatocytes. In particular, exosomal transfer of HCV RNA from hepatocytes to neighboring pDCs can stimulate high-level type I and type III IFN production through TLR7, as well as through RIG-I signaling 94, 98 , whereas Kupffer cells may be able to phagocytose HCV 92 to stimulate local type I and type III IFN production. Although this local production of IFN could serve an obvious antiviral function for suppression of acute HCV infection, chronically produced IFN (particularly IFN-a) also regulates ISG expression and antiviral function that limits the efficacy of both the local hepatic IFN and IFN therapy 69, 89 . During HCV infection, cytokines produced by pDCs, Kupffer cells and infected hepatocytes within the liver could also have an impact on the recruitment of immune cells to the liver, including myeloid cells, NK cells and T cells. HCV regulation of this cytokine induction could be crucial in dictating activation of these immune cells for an effective adaptive immune response to HCV, resulting in changes in HCV-induced pathogenesis and varying outcomes of IFN therapy 14 . This cross-talk between liver cell subtypes would be expected to be influenced by the patient IFNL3 genotype, with those with the favorable genotype having increased immune cell
The polymorphisms in IFNL3 associated with response to treatment are not wholly predictive of HCV therapy and infection outcome, as between 20-40% of those patients with the favorable IFNL3 genotype do not respond to current IFN-based therapy 6, 9, 10 . Therefore, other factors must contribute to a successful outcome of therapy. In fact, the strongest predictor of response to therapy is dictated by the pretreatment expression pattern of ISG mRNA within the liver 69, 70, 91 . Patients with pretherapy induction of ISG mRNA in hepatocytes achieve the lowest therapy response rates. Although it is not known why this correlates to lower therapy response rates, it is possible that the pretherapy induction of ISGs prevents further induction of ISG expression by IFN-a during therapy as a result of activation of negative regulators leading to refractoriness to signaling 89 , or that PKR translational suppression of ISGs prevents their effector function, precluding effective therapy responses 37, 89 (see Fig. 2 ). Interestingly, in Kupffer cells, the resident liver macrophages, the pretherapy induction level of ISGs is also a strong predictor of therapy response 71 . In Kupffer cells, the phenotype is opposite of that seen in hepatocytes, with virtually all nonresponders lacking pretherapy induction of ISGs, whereas responders have strongly induced ISGs 91 . This suggests that during HCV infection, Kupffer cells (activated to induce ISGs, either by cytokine signaling or through phagocytosis and sensing of viral products 75, 92 ; Fig. 5 ) may have a key protective role for the host in both therapy responses and HCV clearance. Understanding how macrophages are activated and how they interact with hepatocytes for immune control during HCV infection and treatment will be essential in determining the mechanisms driving both this phenotype and HCV pathogenesis.
Why do some patients have pretherapy induction of ISGs in hepatocytes and others do not? It is known that host genetic differences and HCV-induced ISG expression profiles in liver-cell subtypes can predict therapy responses. However, they are often independent predictors of therapy responses, meaning that the patient IFNL3 genotype cannot definitively predict the hepatic ISG activation state 70, 91, 93 . Thus, the ISG expression profile of hepatocytes and macrophages is still the single best predictor of therapy response, where virtually all patients that lack preinduced hepatic ISGs respond to therapy, whereas those who lack preinduced macrophage ISGs fail therapy 91 . Therefore, the host genotype at IFNL3 or other host loci and the viral genotype likely predispose the HCV-infected patient to a particular therapy response outcome, but it is a combination of factors, including cross-talk between liver cell subtypes and environmental factors (such as age, race and sex) that ultimately dictates the response to therapy (Fig. 3b) .
Endogenous hepatic IFN regulates innate immunity to HCV
The hepatic pretherapy ISG mRNA expression profiles of some patients with chronic HCV infection indicates that IFN (either type I or type III) 
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genotype is only one of the factors that predict therapy responses (Fig.  2b) . Knowledge of an individual's IFNL3 genotype could be used to guide therapy decisions, but further genetic studies to define additional host factors that affect HCV clearance, disease progression or both will help determine what dictates successful immune responses and treatment outcomes in HCV infection. It is quite likely that an upcoming treatment era for HCV may fully embrace direct-acting antivirals, such as NS3 protease, NS5A replication complex or NS5B polymerase inhibitors, in the absence of IFN combination therapy. Although these therapies are providing a major step forward in treating HCV-infected patients, viral breakthrough and drug resistance will need to be considered and monitored carefully 100 . In addition, the efficacy of these drugs for HCV genotypes other than genotype 1 still needs to be determined.
Research to continue onward in these exciting discoveries and developments will no doubt reveal the key factors required for successful immunity to HCV. In the coming age of personalized medicine, this knowledge could lead to individually tailored HCV therapies based on knowledge of both host and viral genotypes. An understanding of these detailed components of an effective immune response to HCV both at the innate and adaptive levels will be useful to guide the development of the long-desired HCV vaccine. function and better viral clearance, as has been suggested 83 . Understanding the crosstalk between liver cell subtypes is now key to defining the complex nature of both type I and type III IFN actions, for priming of the adaptive immune response (especially generation of virus-specific cytotoxic T lymphocytes) and for influencing therapy outcome and suppressing HCV.
Summary and insights
Although the immune response can clear HCV 43 , virus exposure often carries forward into a chronic infection. Chronic HCV is linked to dysregulation of innate and adaptive immune signaling and viralinduced cytotoxicity and apoptosis in the hepatic environment, which together affect infection outcome and response to therapy and probably contribute to liver fibrosis and cirrhosis. HCV accomplishes this immune dysregulation by evading the host innate immune response at multiple points to prevent the initial coordination of innate immunity that primes the entire immune response, including adaptive immunity, which leads to increased viral replication and contributes to viral persistence. Within the liver microenvironment, multiple cell types contribute to the immune response toward HCV, and interruption of any aspect of the innate response by HCV could lead to an unbalanced, ineffective immune response, both in natural and treatmentinduced HCV clearance, that could drive the progression to liver disease. A full understanding of how viral immune modulation affects infection outcome will require definition of the spectrum of antiviral and immunomodulatory cytokines that govern the cross-talk between the various cell types within the complex liver tissue. For example, how do IFN-a and IFN-l responses cross-talk to one another and with hepatic responses to proinflammatory cytokines, such as IL-1b, IP10 and others, implicated in hepatic inflammation? What are the key producer cells for these cytokines in the infected liver, and how is production of these cytokines stimulated and/or regulated during HCV infection? There may also be a role for hepatic stellate cells in mediating some of these processes, as they have recently been implicated in driving inflammatory responses during HCV infection of hepatocytes 99 .
Clinical trials of IFN-l are already showing that it has great promise as an effective antiviral cytokine treatment, with fewer side effects than observed in patients undergoing IFN-a-based therapy. Although genetic studies have revealed insights on IFNL3 polymorphisms and their linkage with an effective immune response that clears HCV, IFNL3 (2) and Kupffer cells (3) . The activation of these cells is required to prime the adaptive immune response to HCV, which plays a major part in eventual viral clearance 16 . Both type I and type III IFN can act on uninfected hepatocytes to induce an antiviral state that limits virus spread. In the infected cell, HCV can evade IFN induction through viral-mediated processes, including NS3-NS4A-mediated cleavage of MAVS and TRIF, affecting the outcome of HCV infection and disease progression. Cross-talk between hepatocytes and hepatic stellate cells during HCV infection has also been shown to induce inflammatory cytokines and chemokines (not depicted here) 99 . IFN-a/b, IFN-a, IFN-b or both.
